利益冲突与临床指南、咨询委员会报告、评论文章及叙述性综述中有利推荐之间的关联:系统综述
该系统综述纳入21项研究,分析106部临床指南、1809份咨询委员会报告、340篇评论文章和497篇叙述性综述,评估经济利益冲突与药物或器械有利推荐之间的关联。合并分析显示,经济利益冲突与有利推荐存在关联(相对风险1.26,95%CI 1.09至1.44),但各文档类型单独分析统计不精确,且非经济利益冲突的影响尚不确定。
要点
- 经济利益冲突与临床指南、咨询委员会报告、评论文章及叙述性综述中药物或器械的有利推荐相关。
- 合并四类文档的相对风险为1.26(95%CI 1.09至1.44),提示关联存在但统计精度有限。
- 非经济利益冲突对推荐的影响尚不明确,且纳入研究存在混杂风险。
核心结论
- 经济利益冲突与临床指南、咨询委员会报告、评论文章和叙述性综述中对药物或器械的有利推荐存在关联。
- 非经济利益冲突是否影响推荐尚不确定。
研究设计与样本
- 系统综述,检索PubMed、Embase、Cochrane方法学注册库(自建库至2020年2月)、参考文献列表、Web of Science和灰色文献。
- 纳入21项研究,分析106部临床指南、1809份咨询委员会报告、340篇评论文章和497篇叙述性综述。
- 采用随机效应模型估计合并相对风险及95%置信区间,经济利益冲突与非经济利益冲突分别分析,四类文档分别分析(预先计划)并合并分析(事后分析)。
主要发现
- 经济利益冲突与临床指南有利推荐的相对风险为1.26(95%CI 0.93至1.69;4项研究,86部指南)。
- 经济利益冲突与咨询委员会报告有利推荐的相对风险为1.20(95%CI 0.99至1.45;4项研究,629份报告)。
- 经济利益冲突与评论文章有利推荐的相对风险为2.62(95%CI 0.91至7.55;4项研究,284篇评论)。
- 经济利益冲突与叙述性综述有利推荐的相对风险为1.20(95%CI 0.97至1.49;4项研究,457篇综述)。
- 合并四类文档分析显示相对风险1.26(95%CI 1.09至1.44)。
关键数值与推荐
- 一项研究探讨专科兴趣,指南作者包含放射科医生与推荐常规乳腺癌筛查的关联:相对风险2.10(95%CI 0.92至4.77;12部临床指南)。
临床怎么用
- 解读临床指南、咨询委员会报告、评论文章和叙述性综述中的药物或器械推荐时,应关注作者的经济利益冲突。
- 对存在经济利益冲突的文档中的有利推荐需谨慎评估,结合其他证据综合判断。
局限性
- 15项研究存在混杂风险,比较的文档可能在利益冲突以外的因素上存在差异(如不同人群使用不同药物)。
- 各文档类型单独分析的统计不精确。
- 非经济利益冲突对推荐的影响尚不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews. DESIGN: Systematic review. ELIGIBILITY CRITERIA: Studies that compared the association between conflicts of interest and favourable recommendations of drugs or devices (eg, recommending a drug) in clinical guidelines, advisory committee reports, opinion pieces (eg, editorials), or narrative reviews. DATA SOURCES: PubMed, Embase, Cochrane Methodology Register (from inception to February 2020), reference lists, Web of Science, and grey literature. DATA EXTRACTION AND ANALYSIS: Two authors independently extracted data and assessed the methodological quality of the studies. Pooled relative risks and 95% confidence intervals were estimated using random effects models (relative risk >1 indicates that documents with conflicts of interest more often had favourable recommendations than documents with no conflicts of interest). Financial and non-financial conflicts of interest were analysed separately, and the four types of documents were analysed separately (preplanned) and combined (post hoc). RESULTS: 21 studies that analysed 106 clinical guidelines, 1809 advisory committee reports, 340 opinion pieces, and 497 narrative reviews were included. Unpublished data were received for 11 studies (eight full datasets and three summary datasets). 15 studies showed risk of confounding because the compared documents could differ in factors other than conflicts of interest (eg, different drugs used for different populations). The relative risk for associations between financial conflicts of interest and favourable recommendations for clinical guidelines was 1.26 (95% confidence interval 0.93 to 1.69; four studies of 86 clinical guidelines), for advisory committee reports was 1.20 (0.99 to 1.45; four studies of 629 advisory committee reports), for opinion pieces was 2.62 (0.91 to 7.55; four studies of 284 opinion pieces), and for narrative reviews was 1.20 (0.97 to 1.49; four studies of 457 narrative reviews). An analysis of all four types of documents combined supported these findings (1.26, 1.09 to 1.44). In one study that investigated specialty interests, the association between including radiologists as authors of guidelines and recommending routine breast cancer was: relative risk 2.10, 95% confidence interval 0.92 to 4.77; 12 clinical guidelines). CONCLUSIONS: We interpret our findings to indicate that financial conflicts of interest are associated with favourable recommendations of drugs and devices in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews. Limitations of this review were risk of confounding in the included studies and the statistical imprecision of individual analyses of each document type. It is not certain whether non-financial conflicts of interest influence recommendations. SYSTEMATIC REVIEW REGISTRATION: Cochrane Methodology Review Protocol MR000040.
引用
- Nejstgaard CH, Bero L, Hróbjartsson A, et al. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. BMJ. 2020. PMID: 33298430. doi:10.1136/bmj.m4234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。